REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Celemics, Inc. (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: Celemics, Inc. Profile Updated: July 08, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company mainly engaged in manufacturing products related to life science medicine. The Company mainly develops and sells target capture kit products. In addition, the Company is engaged in immune repertoire analysis solutions and next-generation sequencing solutions. The Company sells its products in domestic and overseas markets. The Company was established on November 29, 2010. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on August 21, 2020.

Headquarters
19F ~ 20F, Bldg. A, Byc Highcity, 131, Gasandigital 1-Ro, Geumcheon-Gu
Seoul; Seoul;

Contact Details: Purchase the Celemics, Inc. report to view the information.

Website: http://www.celemics.com

Basic Information
Total Employees:
Purchase the Celemics, Inc. report to view the information.
Outstanding Shares:
Purchase the Celemics, Inc. report to view the information.
Registered Capital:
Purchase the Celemics, Inc. report to view the information.
Financial Auditors:
Purchase the Celemics, Inc. report to view the information.
Incorporation Date:
November 29, 2010
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
(주)아이엠비디엑스
Company Performance
Financial values in the chart are available after Celemics, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
-18.64%▼
Total operating revenue
-20.94%▼
Operating profit (EBIT)
0.12%▲
EBITDA
-0.18%▼
Net Profit (Loss) for the Period
26.01%▲
Total assets
-32.64%▼
Total equity
-32.09%▼
Operating Profit Margin (ROS)
-16.22%▼
Net Profit Margin
5.87%▲
Return on Equity (ROE)
-2%▼
Debt to Equity Ratio
-1.6%▼
Quick Ratio
-3.87%▼
Cash Ratio
-1.38%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo